Cologuard is included in major colorectal
cancer (CRC) screening guidelines and
quality measures1-9

of credit

Healthcare Effectiveness Data and Information Set (HEDIS®)1*

Cologuard is a part of the standard of care for CRC screening
  • US Preventive Services Task Force (USPSTF)2
  • American Cancer Society (ACS)3
  • National Comprehensive Cancer Network® (NCCN®)4
  • American College of Obstetricians and Gynecologists (ACOG)5
  • Medicare Access and CHIP Reauthorization Act of 2015 (MACRA)6
  • Medicare Advantage Stars Rating Program7
  • Electronic Clinical Quality Measure (eCQM)8
  • Health Resources and Services Administration Uniform Data Set (UDS)9
Cologuard is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. A positive result may indicate the presence of colorectal cancer (CRC) or advanced adenoma (AA) and should be followed by diagnostic colonoscopy. Cologuard is indicated to screen adults of either sex, 45 years or older, who are at typical average risk for CRC. Cologuard is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals.